Lifecore Biomedical, Inc. (NASDAQ:LFCR – Free Report) – Analysts at Barrington Research lowered their Q4 2024 earnings per share (EPS) estimates for Lifecore Biomedical in a research report issued to clients and investors on Friday, September 1st. Barrington Research analyst M. Petusky now forecasts that the company will post earnings per share of $0.16 for the quarter, down from their previous forecast of $0.21. Barrington Research has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.96) per share.
Separately, Stephens upped their target price on shares of Lifecore Biomedical from $8.00 to $9.00 and gave the company an “equal weight” rating in a research note on Friday.
Lifecore Biomedical Stock Down 1.6 %
NASDAQ LFCR opened at $7.87 on Monday. The company has a quick ratio of 1.05, a current ratio of 2.35 and a debt-to-equity ratio of 3.36. Lifecore Biomedical has a fifty-two week low of $1.52 and a fifty-two week high of $11.45. The business has a 50 day moving average price of $9.64 and a two-hundred day moving average price of $6.94. The stock has a market cap of $238.63 million, a PE ratio of -2.31 and a beta of 1.09.
Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) last announced its earnings results on Thursday, June 1st. The company reported ($0.22) EPS for the quarter. The company had revenue of $27.60 million for the quarter. Lifecore Biomedical had a negative net margin of 64.29% and a negative return on equity of 35.52%. During the same quarter in the prior year, the firm posted ($0.08) EPS.
Hedge Funds Weigh In On Lifecore Biomedical
A number of institutional investors have recently made changes to their positions in LFCR. Wynnefield Capital Inc. bought a new stake in Lifecore Biomedical in the second quarter valued at about $47,611,000. Cove Street Capital LLC bought a new stake in shares of Lifecore Biomedical in the 2nd quarter valued at approximately $15,661,000. BlackRock Inc. acquired a new stake in shares of Lifecore Biomedical during the 2nd quarter valued at approximately $5,145,000. Visionary Wealth Advisors acquired a new stake in shares of Lifecore Biomedical during the 2nd quarter valued at approximately $4,828,000. Finally, Geode Capital Management LLC bought a new position in Lifecore Biomedical during the second quarter worth $2,771,000. 75.85% of the stock is owned by institutional investors and hedge funds.
About Lifecore Biomedical
Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.
- Five stocks we like better than Lifecore Biomedical
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 8/28 – 9/1
- How to Invest in Apparel Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.